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Protection Against Adverse Birth Outcomes Related to Malaria 
and Sexually Transmitted and Reproductive Tract Infections
R. Matthew Chico,1 Enesia Banda Chaponda,1,2 Cono Ariti,3 and Daniel Chandramohan1
1Department of Disease Control, London School of Hygiene & Tropical Medicine, United Kingdom; 2Department of Biological Sciences, University of Zambia, Lusaka; and 3Department of Medical 
Statistics, London School of Hygiene & Tropical Medicine, United Kingdom
Background. We conducted a prospective cohort study in Zambia among pregnant women who received intermittent preven-
tive treatment using sulfadoxine-pyrimethamine (IPTp-SP).
Methods. We calculated the odds ratios (ORs) of adverse birth outcomes by IPTp-SP exposure, 0–1 dose (n = 126) vs ≥2 doses 
(n = 590) and ≥2 doses (n = 310) vs ≥3 doses (n = 280) in 7 categories of malaria infection and sexually transmitted and reproductive 
tract infections (STIs/RTIs).
Results. We found no significant differences in baseline prevalence of infection across IPTp-SP exposure groups. However, 
among women given 2 doses compared to 0–1 dose, the odds of any adverse birth outcome were reduced 45% (OR, 0.55; 95% con-
fidence interval [CI], 0.36, 0.86) and 13% further with ≥3 doses (OR, 0.43; 95% CI, 0.27, 0.68). Two or more doses compared to 0–1 
dose reduced preterm delivery by 58% (OR, 0.42; 95% CI, 0.27, 0.67) and 21% further with ≥3 doses (OR, 0.21; 95% CI, 0.13, 0.35). 
Women with malaria at enrollment who received ≥2 doses vs 0-1 had 76% lower odds of any adverse birth outcome (OR, 0.24; 95% 
0.09, 0.66), and Neisseria gonorrhoeae and/or Chlamydia trachomatis had 92% lower odds of any adverse birth outcome (OR, 0.08; 
95% CI, 0.01, 0.64). Women with neither a malaria infection nor STIs/RTIs who received ≥2 doses had 73% fewer adverse birth 
outcomes (OR, 0.27; 95% CI, 0.11, 0.68).
Conclusions. IPTp-SP appears to protect against malaria, STIs/RTIs, and other unspecified causes of adverse birth outcome.
Keywords. malaria; curable sexually transmitted infections; antenatal care; intermittent preventive treatment; sub-Saharan 
Africa.
 
To reduce the adverse consequences of malaria infection 
during pregnancy, the World Health Organization (WHO) 
recommends administering sulfadoxine-pyrimethamine 
(SP) as intermittent preventive treatment (IPTp) to women 
during every scheduled antenatal care (ANC) visit at least 
1 month apart during the second trimester and at delivery in 
areas of moderate to high malaria transmission [1]. Although 
the WHO recommendation for IPTp-SP does not extend to 
low-transmission settings, a recent metaregression analy-
sis suggests there is not a threshold of malaria transmission 
intensity below which ≥2 doses of IPTp-SP are no longer pro-
tective against the incidence of low birth weight (LBW) in 
sub-Saharan Africa [2]. One possible reason could be that 
IPTp-SP is protective against malaria as well as other nonma-
larial causes of LBW. Five curable sexually transmitted and 
reproductive tract infections (STIs/RTIs)—syphilis, Neisseria 
gonorrheae, Chlamydia trachomatis, Trichomonas vaginalis, 
and bacterial vaginosis—are associated with several adverse 
birth outcomes that include stillbirth [3–5], LBW [4–9], pre-
term birth [5, 8, 10–13], and intrauterine growth retardation 
(IUGR) [4, 5]. Thus, we analyzed data from a prospective 
cohort of pregnant women, relating the incidence of malaria 
infection and curable STIs/RTIs, maternal exposure to 
IPTp-SP during the antenatal period (0–1 doses vs ≥2 doses 
and, separately, 2 doses vs ≥3 doses), and the resulting inci-
dence of the following 4 adverse birth outcomes: stillbirth, 
LBW, preterm delivery, and IUGR.
METHODS
We recruited 1086 pregnant women between November 2013 
and April 2014 on their first ANC visit to health centers oper-
ated by the Ministry of Health in the Nchelenge District of 
Zambia as described elsewhere [14, 15]. Nchelenge is in the 
Luapula province 290 km (180 miles) from Mansa, the provin-
cial capital, and along the shores of Lake Mweru in northeastern 
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Zambia. Gestational age was measured at enrollment to deter-
mine eligibility for participation and was based on last menstrual 
period, symphysis-fundal height, and sonography. Women who 
were not already known to have AIDS were tested for human 
immunodeficiency virus (HIV) per ministry practices at the 
time. HIV-infected women were given triple antiretroviral ther-
apy if their CD4 count was <500 cells/mm3 of blood, a variation 
on “option B” treatment originally recommended by the WHO 
in 2010 [16]. Study staff tested women for syphilis using rapid 
plasma reagin (RPR) methods. If positive, women received a 
written notice to return to the health facility with their part-
ners for treatment. Biological samples for malaria and other 
curable STIs/RTIs were collected at enrollment and transported 
to a reference laboratory for retrospective batch-testing using 
polymerase chain reaction techniques. Placental samples were 
collected at delivery for malaria histology. Women were given 
IPTp-SP during scheduled ANC visits and followed through 
delivery to record birth outcomes. Women were encouraged to 
deliver at a health facility to simplify data collection. If willing 
to do so, the women were provided free transport to and from 
the only hospital in the district, Saint Paul’s Mission Hospital, 
or Kashikishi Health Centre; Nchelenge Health Center did not 
offer maternity services at the time. We analyzed data using 
Stata, version 13 (StataCorp, College Station, Texas) software.
Descriptive Analysis
We summarized categorical variables as whole numbers and 
percentages and continuous variables by means and standard 
deviations if the data appeared to be normally distributed. 
We then assessed the differences in the characteristics of par-
ticipants at the time of enrollment between women who had 
received 0–1 dose vs ≥2 doses and, separately, 2 doses vs ≥ 
3 doses, using Wilcoxon test for continuous variables and 
Fisher exact test for categorical variables. We then calculated 
the crude odds ratios (ORs) of adverse birth outcomes among 
pregnant women who received 0–1 dose compared to ≥2 
doses and 2 doses compared to ≥3 doses with logistic regres-
sion models.
Assessment of Confounding and Effect Modification
At the onset, we considered HIV status and gravidae to be con-
founders on the protective effect of IPTp-SP against adverse 
birth outcomes based on evidence in the public domain [17, 
18]. We used common statistical methods to identify other 
potential confounders [19], entering variables into a logistic 
regression model that included categories of IPTp-SP exposure. 
We considered variables to be confounders a priori if they pro-
duced a change in ORs between crude and adjusted by ≥10% 
(Supplementary Tables 2–6). We tested effect modification by 
adding an interaction term between these potential confound-
ers and the number of IPTp-SP doses and then applied a like-
lihood ratio test to see if there was evidence of interaction. We 
observed some evidence of effect modification with malaria and 
ST/RT coinfection, which we dealt with separately as described 
below. We also considered malaria and ST/RT coinfection as 
a confounder. We then entered all confounding variables into 
a multivariable logistic regression model to estimate overall 
adjusted ORs.
Calculation of Coinfection Odds Ratios
We examined the distribution of infection and constructed the 
following 7 mutually exclusive maternal infection categories: 
malaria only, malaria and N. gonorrhoeae and/or C. trachoma-
tis, malaria and T. vaginalis and/or bacterial vaginosis, syphilis 
and any other infection(s), N. gonorrhoeae, C. trachomatis only, 
T.  vaginalis and/or bacterial vaginosis only, and no identified 
infection. We then calculated stratum-specific ORs of IPTp-SP 
exposure for each infection category using a multivariable logis-
tic regression model that included all potential confounders as 
well as interaction terms.
RESULTS
We found no significant differences in the prevalence of malaria 
infection and curable STIs/RTIs at baseline across IPTp-SP expo-
sure groups stratified by 0–1 dose (n = 126) vs ≥2 doses (n = 590; 
Table 1) and, separately, 2 doses (n = 310) vs ≥3 doses (n = 280) 
(Supplementary Table 1). However, the odds of any adverse birth 
outcome among women who received ≥2 doses compared to 
0–1 dose (Table 2) were reduced 45% (OR, 0.55; 95% confidence 
interval [CI], 0.36, 0.86) and 12% further (57% total reduction) 
with ≥3 doses (OR, 0.43; 95% CI, 0.27, 0.68). Two or more doses 
compared to 0–1 dose reduced the odds of preterm delivery by 
58% (OR, 0.42; 95% CI, 0.27, 0.67) and 21% further (79% total 
reduction) with ≥3 doses (OR, 0.21; 95% CI, 0.13, 0.35; Table 2).
This dose-response relationship was also observed against 
malaria infection and STIs/RTIs in IPTp-SP dosing categories 
of 0–1 vs ≥2 doses and 2 vs ≥ 3 doses. In 24 of 30 infection cat-
egories, ≥2 doses conferred greater protection against adverse 
birth outcomes than 0–1 dose, 8 of which showed significant 
effects (Table  3); 3 categories related to any birth outcome, 1 
was specific to LBW, and 4 were associated with preterm birth.
Women who had malaria only at enrollment and received ≥2 
doses of versus 0-1 had 76% lower odds of any adverse birth 
outcome (OR, 0.24; 95% 0.09, 0.66), whereas women who had 
N. gonorrhoeae and/or C. trachomatis at enrollment and were 
provided ≥2 doses of versus 0-1, had 92% lower odds of any 
adverse birth outcome (OR, 0.08; 95% CI, 0.01, 0.64). Women 
with neither a malaria infection nor STIs/RTIs and who received 
≥2 doses, rather than 0–1 dose, had 73% fewer adverse birth 
outcomes (OR, 0.27; 95% CI, 0.11, 0.68). Similarly, women with 
neither a malaria infection nor STIs/RTIs and who received ≥2 
doses had the odds of LBW reduced by 76% (OR, 0.24; 95% CI, 
0.08, 0.68).
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Table  1. Participant Characteristics by Exposure to 0–1 Dose vs ≥ 2 
Doses of Intermittent Preventive Treatment Against Malaria Using 
Sulfadoxine-Pyrimethamine
Characteristic at Enrollment
Doses of Sulfadoxine-
Pyrimethamine Received, no. (%)a
P Valueb
0–1 Dose ≥2 Doses
n = 126 n = 590
Age of participants .498
 Mean (standard deviation) 25.8 (6.5) 25.4 (6.4)
 Median (interquartile 
range)
24.0 (20.0, 31.0) 24.0 (20.0, 30.0)
Marital status .175
 Single 19 (15.1) 123 (20.8)
 Married, divorced/sepa-
rated, or widowed
107 (84.9) 467 (79.2)
Age at sexual debut, y .733
 <15 13 (10.3) 49 (8.3)
 ≥15 96 (76.2) 455 (77.1)
 Unknown 17 (13.5) 86 (14.6)
Number of lifetime sexual 
partners
.362
 1 52 (41.3) 272 (46.6)
 2 45 (35.7) 161 (27.6)
 3 18 (14.3) 94 (16.1)
 4 or more 11 (8.7) 57 (9.8)
Gravidae .301
 Primigravidae 27 (21.4) 165 (28.0)
 Secundigravidae 19 (15.1) 77 (13.1)
 Multigravidae 80 (63.5) 348 (59.0)
Wealth quintiles .048
 Lowest 21 (16.7) 115 (19.5)
 Second 32 (25.4) 111 (18.8)
 Middle 31 (24.6) 113 (19.2)
 Fourth 14 (11.1) 122 (20.7)
 Highest 28 (22.2) 129 (21.9)
Bed net ownership .493
 No 68 (54.0) 297 (50.3)
 Yes 58 (46.0) 293 (49.7)
Used insecticide-treated net 
on previous night
.840
 No 77 (61.1) 366 (62.4)
 Yes 49 (38.9) 221 (37.6)
 Missing 0 3
Indoor residual spraying in 
the previous 12 months
.186
 No 103 (83.1) 439 (77.6)
 Yes 21 (16.9) 127 (22.4)
 Missing 2 24
Experienced miscarriage 
before
.869
 No 86 (86.9) 371 (87.3)
 Yes 13 (13.1) 54 (12.7)
 None reported by 
primigravidae
27 165
Delivered a premature baby 
before
1.000
 No 94 (94.9) 401 (94.4)
 Yes 5 (5.1) 24 (5.6)
 Not applicable to 
primigravidae
27 165
Characteristic at Enrollment
Doses of Sulfadoxine-
Pyrimethamine Received, no. (%)a
P Valueb
0–1 Dose ≥2 Doses
n = 126 n = 590
Delivered a stillborn before .307
 No 94 (94.9) 387 (91.1)
 Yes 5 (5.1) 38 (8.9)
 Not applicable to 
primigravidae
27 165
Human immunodeficiency 
virus status
.186
 Negative 105 (83.3) 519 (88.0)
 Positive 21 (16.7) 71 (12.0)
Malaria and curable STIs/RTIs
 Malaria (polymerase chain 
reaction diagnosis)
62 (49.2) 346 (59.3) .047
 Syphilis (high titer) 1 (0.8) 17 (2.9) .223
 Neisseria gonorrhoeae 1 (0.8) 21 (3.6) .152
 Chlamydia trachomatis 8 (6.3) 26 (4.4) .357
 Trichomonas vaginalis 30 (23.8) 140 (23.7) 1.000
 Bacterial vaginosis 59 (46.8) 277 (46.9) 1.000
Characteristics at Delivery
Place of delivery .233
 Hospital 119 (94.4) 551 (93.4)
 Clinic 1 (0.8) 19 (3.2)
 Home 6 (4.8) 20 (3.4)
Delivery performed by .240
 Doctor 3 (2.4) 38 (6.4)
 Midwife 115 (91.3) 524 (88.8)
 Family member 5 (4.0) 17 (2.9)
 Other 3 (2.4) 11 (1.9)
Type of labor .296
 Spontaneous 126 (100.0) 558 (97.4)
 Induced 0 (0.0) 9 (1.6)
 Augmented 0 (0.0) 6 (1.0)
Type of delivery .092
 Vaginal 123 (97.6) 551 (93.4)
 Cesarean section 3 (2.4) 39 (6.6)
Hypertension .296
 No 110 (96.5) 506 (98.1)
 Yes 4 (3.5) 10 (1.9)
Maternal hemoglobin .786
 Normal 103 (85.1) 470 (83.5)
 Anemic 18 (14.9) 93 (16.5)
Sex of baby .008
 Female 78 (61.9) 287 (48.6)
 Male 48 (38.1) 303 (51.4)
Received curative treatment 
for malaria infection
.102
 No 115 (92.0) 508 (86.4)
 Yes 10 (8.0) 80 (13.6)
Received curative treatment 
for any STI/RTI
1.000
 Untreated 116 (92.1) 540 (91.5)
 Treated 10 (7.9) 50 (8.5)
aAge is shown as the median value with the interquartile range in parentheses.
bP values are from Wilcoxon rank sum test (continuous variables) or Fisher exact test 
(categorical variables).
Abbreviations: STI, sexually transmitted infections; RTI, reproductive tract infections.
Table 1. Continued
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Women who had malaria only at enrollment and received 
≥2 doses of versus 0-1, had 81% lower odds of preterm birth 
(OR, 0.19; 95% CI, 0.07, 0.53), whereas participants who had 
malaria plus T. vaginalis and/or bacterial vaginosis at enroll-
ment and received ≥2 doses of versus 0-1, had 55% lower odds 
of preterm birth (OR, 0.45; 95% CI, 0.21, 0.97).  In the same 
way, women who had N. gonorrhoeae or C. trachomatis at 
enrollment and received ≥2 doses of versus 0-1, had 93% lower 
odds of preterm birth (OR, 0.07; 95% CI, 0.01, 0.73), and those 
who had neither malaria nor any curable STI/RTI at enrollment 
and received ≥2 doses of versus 0-1, had 80% lower odds of pre-
term birth (OR, 0.20; 95% CI, 0.07, 0.54).
This dose-response effect extended, although less pro-
nounced, in comparisons of outcomes following ≥3 doses vs 2 
doses (Table 4). There appeared to be a trend of protection in 17 
of 31 infection categories conferred by ≥3 doses vs 2 doses, but 
this protective effect was only significant in 2 infection categories 
(Table 4). Women who had malaria plus T. vaginalis and/or bac-
terial vaginosis at enrollment and received ≥3 doses vs 2 doses 
had 67% lower odds of preterm birth (OR, 0.33; 95% CI, 0.15, 
0.73), whereas participants who had T. vaginalis and/or bacterial 
vaginosis at enrollment and received ≥3 doses vs 2 doses had 
66% lower odds of preterm birth (OR, 0.34; 95% CI, 0.13, 0.94).
DISCUSSION
To our knowledge, we are the first to investigate the association 
between the number of IPTp-SP doses and malaria, curable STIs/
RTIs, and birth outcomes. One of our most interesting findings 
was that women who received ≥2 doses and had neither malaria 
nor curable STIs/RTIs were more protected against any adverse 
birth outcome, LBW, and preterm delivery compared to recipi-
ents of 0–1 dose. It appears that no additional benefit is conferred 
to pregnant women against nonmalaria and non-STI/RTI causes 
of adverse birth outcomes when ≥3 doses are administered.
These findings may partially explain why IPTp-SP has 
demonstrated noninferiority against more potent antima-
larial compounds in several randomized clinical trials of 
IPTp, particularly in studies measuring LBW and preterm 
birth as endpoints [20–24]. Sulfadoxine is a broad-spec-
trum antibiotic that likely exerts an inhibitory effect against 
nonmalaria causes of LBW and preterm birth [25]. SP has 
been used to prevent Pneumocystis jiroveci pneumonia and 
Toxoplasma gondii infection [26]. Sulfadoxine is pharmaco-
logically related to sulfamethoxazole, a compound coformu-
lated with trimethoprim for the treatment of urinary tract 
infections and to prevent P. jiroveci among HIV-infected 
patients [27]. Prior to the development of penicillin, sulfo-
namides were used to treat N. gonorrhoeae [28]. Based on 
historical use, sulfonamides could exert some effect on C. tra-
chomatis, Streptococcus pyogenes, Streptococcus pneumoniae, 
and Haemophilus influenzae, among many other pathogens 
[29]. Sulfonamides have also been used to treat Gardnerella 
vaginalis [30], a bacterium that is commonly found in high 
concentrations among women with bacterial vaginosis. Thus, 
Table  2. Adverse Birth Outcomes by Exposure to 0–1 Dose vs 2 Doses vs ≥ 3 Doses of Intermittent Preventive Treatment Against Malaria Using 
Sulfadoxine-Pyrimethamine
Birth Outcome No. of Women Outcomes Unadjusted OR 95% CI Adjusted ORa 95% CI P Valueb
Any adverse outcome
 0–1 dose 126 58 1.00 1.00 .002
 2 doses 310 108 0.63 0.41, 0.96 0.55 0.36, 0.86
 ≥3 doses 280 84 0.50 0.33, 0.78 0.43 0.27, 0.68
Stillbirth
 0–1 dose 126 4 1.00 1.00 .143
 2 doses 310 2 0.20 0.04, 1.10 0.21 0.04, 1.19
 ≥3 doses 280 6 0.67 0.19, 2.41 0.68 0.18, 2.57
Low birth weight
 0–1 dose 126 32 1.00 1.00 .261
 2 doses 310 67 0.80 0.49, 1.30 0.71 0.42, 1.19
 ≥3 doses 280 57 0.74 0.45, 1.22 0.64 0.37, 1.09
Preterm delivery
 0–1 dose 126 50 1.00 1.00 <0.001
 2 doses 310 71 0.45 0.29, 0.71 0.42 0.27, 0.67
 ≥3 doses 280 37 0.23 0.14, 0.38 0.21 0.13, 0.35
Intrauterine growth retardation
 0–1 dose 126 7 1.00 1.00 .318
 2 doses 310 34 1.64 0.70, 3.87 1.55 0.64, 3.77
 ≥3 doses 280 43 2.12 0.91, 4.93 1.88 0.78, 4.54
CIs that do not overlap the null value of OR = 1 are shown in bold.
Abbreviations: CI, confidence interval; OR, odds ratio.
aAdjusted for sexually transmitted and reproductive tract coinfection, gravidae, and human immunodeficiency virus coinfection.
bP value for likelihood ratio test.
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even if sulfadoxine is only partially protective against a broad 
spectrum of gram-positive and gram-negative bacteria, dos-
ing at each scheduled ANC visit from the second trimester 
to delivery may be sufficient to curb bacterial densities, thus 
directly reducing the incidence of adverse birth outcomes. It 
is possible, as well, that reduced bacterial densities produced 
Table 3. Categories of Maternal Infection and Exposure to Dose 0–1 vs ≥ 2 Doses of Intermittent Preventive Treatment Against Malaria Using Sulfadoxine-
Pyrimethamine Among Women with Adverse Birth Outcomes
Adverse Birth Outcome 0–1 dose IPTp-SP ≥2 doses IPTp-SP
Categories of Maternal Infection
No. of  
Women
No. of  
Outcomes
No. of  
Women
No. of 
Outcomes Crude OR 95% CI Adjusted ORa 95% CI
Any adverse outcome
 Malaria only 20 13 129 41 0.25 0.09, 0.88 0.24 0.09, 0.66
 Malaria and NG and/or CT 3 1 27 11 1.38 0.11, 17.09 1.17 0.09, 15.89
 Malaria and TV and/or BV 38 15 182 67 0.89 0.44, 1.83 0.96 0.45, 2.02
 Syphilis and any other 
infection(s)b
1 1 17 7 0.80 0.00, 31.20 0.80 0.00, 31.20
 NG and/or CT only 6 4 14 2 0.08 0.01, 0.80 0.08 0.01, 0.64
 TV and/or BV only 32 12 124 42 0.85 0.38, 1.91 0.72 0.32, 1.65
 No identified infection 26 12 97 22 0.34 0.14, 0.85 0.27 0.11, 0.68
Stillbirth
 Malaria only 20 1 129 1 0.15 0.01, 2.54 0.15 0.01, 2.54
 Malaria and NG and/or CT 3 0 27 0 NA NA NA NA
 Malaria and TV and/or BV 38 0 182 3 0.81 0.09, Inf 0.81 0.09, Inf
 Syphilis and any other 
infection(s)
1 1 17 0 0.06 0.00, 2.29 0.06 0.00, 2.29
 NG and/or CT only 6 0 14 0 NA NA NA NA
 TV and/or BV only 32 1 124 3 0.76 0.07, 7.86 0.76 0.07, 7.86
 No identified infection 26 1 97 1 0.26 0.02, 4.31 0.22 0.01, 3.79
Low birth weight
 Malaria only 20 6 129 25 0.56 0.20, 1.60 0.59 0.19, 1.82
 Malaria and NG and/or CT 3 1 27 7 0.7 0.05, 8.97 0.49 0.03, 7.35
 Malaria and TV and/or BV 38 10 182 46 0.95 0.43, 2.10 1.08 0.46, 2.54
 Syphilis and any other 
infection(s)
1 0 17 5 NA NA NA NA
 NG and/or CT only 6 2 14 1 0.15 0.01, 2.18 0.12 0.01, 1.90
 TV and/or BV only 32 5 124 27 1.5 0.53, 4.27 1.22 0.41, 3.59
 No identified infection 26 8 97 13 0.35 0.13, 0.96 0.24 0.08, 0.68
Preterm delivery
 Malaria only 20 10 129 21 0.19 0.07, 0.53 0.19 0.07, 0.53
 Malaria and NG and/or CT 3 0 27 6 NA NA NA NA
 Malaria and TV and/or BV 38 14 182 37 0.44 0.21, 0.93 0.45 0.21, 0.97
 Syphilis and any other 
infection(s)
1 1 17 5 0.50 0.00, 19.50 0.50 0.00, 19.50
 NG and/or CT only 6 4 14 2 0.08 0.01, 0.80 0.07 0.01, 0.73
 TV and/or BV only 32 11 124 25 0.48 0.21, 1.13 0.43 0.18, 1.03
 No identified infection 26 10 97 12 0.23 0.08, 0.61 0.20 0.07, 0.54
Intrauterine growth retardation
 Malaria only 20 2 129 18 0.8 0.16, 4.08 0.75 0.14, 4.05
 Malaria and NG and/or CT 3 1 27 5 0.62 0.05, 8.43 0.54 0.03, 8.43
 Malaria and TV and/or BV 38 1 182 27 5.35 0.69, 41.40 6.11 0.76, 49.13
 Syphilis and any other 
infection(s)
1 0 17 2 NA NA NA NA
 NG and/or CT only 6 0 14 0 NA NA NA NA
 TV and/or BV only 32 1 124 16 3.81 0.48, 30.44 3.13 0.38, 25.68
 No identified infection 26 2 97 9 0.83 0.16, 4.25 0.66 0.12, 3.57
CIs that do not overlap the null value of OR = 1 are shown in bold. Syphilis and coinfection describes pregnant women who tested positive for syphilis using rapid plasma reagin assays 
and were also infected with malaria and/or another curable sexually transmitted or reproductive tract infection. NA (not applicable) is used where there are no observations in the reference 
group (0–1 dose). Inf (infinity) is used where the subsample of outcomes observed is too small to produce an outer limit with certainty.
Abbreviations: BV, bacterial vaginosis; CI, confidence interval; CT, Chlamydia trachomatis; IPTp-SP, intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimeth-
amine; NG, Neisseria gonorrhoeae; OR, odds ratio; TV, Trichomonas vaginalis. 
aAdjusted for sexually transmitted and reproductive tract coinfection, gravidae, and human immunodeficiency virus coinfection.
bSyphilis and any other infection(s) refers to any other curable sexually transmitted or reproductive tract infection and/or malaria.
1048 • CID 2017:64 (15 April) • Chico et al
by sulfadoxine exposure also inhibit maternal inflammatory 
responses to infections that are known to trigger preterm 
birth [31].
Although we found no statistically significant differences 
across exposure groups in the baseline characteristics specific 
to malaria infection and curable STIs/RTIs, our analyses did 
Table 4. Categories of Maternal Infection and Exposure to 2 Doses vs ≥ 3 Doses of Intermittent Preventive Treatment Against Malaria Using Sulfadoxine-
Pyrimethamine Among Women With Adverse Birth Outcomes
Adverse Birth Outcomes 2 Doses IPTp-SP ≥3 Doses IPTp-SP
Categories of Maternal 
Infection
No. of 
Women
No. of 
Outcomes
No. of 
Women
No. of 
Outcomes Crude OR 95% CI
Adjusted 
ORa 95% CI
Any adverse outcome
 Malaria only 66 23 63 18 0.75 0.35, 1.58 0.72 0.33, 1.56
 Malaria and NG and/or CT 18 7 9 4 1.26 0.25, 6.36 0.93 0.17, 5.16
 Malaria and TV and/or BV 86 36 96 31 0.66 0.36, 1.21 0.66 0.35, 1.24
 Syphilis and any other 
infection(s)b
7 3 10 4 0.89 0.13, 6.31 0.5 0.07, 3.72
 NG and/or CT only 12 1 2 1 11 0.35, 345.05 16.39 0.50, 541.53
 TV and/or BV only 71 27 53 15 0.64  0.30, 1.38 0.64 0.29, 1.41
 No identified infection 50 11 47 11 1.08 0.42, 2.80 1.28 0.48, 3.43
Stillbirth
 Malaria only 66 1 63 0 1.03 0.00, 40.32 1.03 0.00, 40.32
 Malaria and NG and/or CT 18 0 9 0 N/A - N/A -
 Malaria and TV and/or BV 86 1 96 2 1.81 0.09, 107.93 1.81 0.09, 107.93
 Syphilis and any other 
infection(s)
7 0 10 0 N/A - N/A -
 NG and/or CT only 12 0 2 0 N/A - N/A -
TV and/or BV only 71 0 53 3 5.32 0.56, Inf 5.32 0.56, Inf
 No identified infection 50 0 47 1 1.81 0.16, 20.30 2.18 0.19, 25.65
Low birth weight
 Malaria only 66 14 63 11 0.79 0.33, 1.89 0.74 0.30, 1.86
 Malaria and NG and/or CT 18 5 9 2 0.74 0.11, 4.87 0.49 0.07, 3.62
 Malaria and TV and/or BV 86 23 96 23 0.86 0.44, 1.68 0.91 0.45, 1.86
 Syphilis and any other 
infection(s)
7 2 10 3 1.07 0.13, 8.98 0.53 0.06, 4.87
 NG and/or CT only 12 1 2 0 6.00 0.00, 234 6.00 0.00, 234
 TV and/or BV only 71 16 53 11 0.90 0.38, 2.14 0.90 0.38, 2.14
 No identified infection 50 6 47 7 1.28 0.40, 4.14 1.59 0.47, 5.40
Preterm delivery
 Malaria only 66 13 63 8 0.59 0.23, 1.55 0.59 0.22, 1.54
 Malaria and NG and/or CT 18 4 9 2 1.00 0.15, 6.85 0.83 0.12, 5.82
 Malaria and TV and/or BV 86 25 96 12 0.34 0.16, 0.74 0.33 0.15, 0.73
 Syphilis and any other 
infection(s)
7 3 10 2 0.33 0.04, 2.87 0.23 0.03, 2.06
 NG and/or CT only 12 1 2 1 11 0.35, 345.06 14.4 0.45, 463.93
 TV and/or BV only 71 19 53 6 0.35 0.13, 0.95 0.34 0.13, 0.94
 No identified infection 50 6 47 6 1.07 0.32, 3.59 1.19 0.35, 4.03
Intrauterine growth retardation
 Malaria only 66 9 63 9 0.96 0.35, 2.63 1.01 0.35, 2.89
 Malaria and NG and/or CT 18 3 9 2 1.47 0.18, 11.72 0.64 0.07, 5.74
 Malaria and TV and/or BV 86 9 96 18 1.52 0.63, 3.65 1.54 0.61, 3.88
 Syphilis and any other 
infection(s)
7 0 10 2 1.31 0.09, Inf 1.31 0.09, Inf
 NG and/or CT only 12 0 2 0 N/A - N/A -
 TV and/or BV only 71 8 53 8 1.15 0.40, 3.36 1.28 0.42, 3.89
 No identified infection 50 5 47 4 0.84 0.21, 3.38 0.88 0.21, 3.70
CIs that do not overlap the null value of OR = 1 are shown in bold. Syphilis and coinfection describes pregnant women who tested positive for syphilis using rapid plasma reagin assays and 
were also infected with malaria and/or another curable sexually transmitted or reproductive tract infection. NA (not applicable) is used where there are no observations in the reference group 
(0–1 dose). Inf (infinity) is used where the subsample of outcomes observed is too small to produce an outer limit with certainty.
Abbreviations: BV, bacterial vaginosis; CI, confidence interval; CT, Chlamydia trachomatis; IPTp-SP, intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimeth-
amine; NG, Neisseria gonorrhoeae; OR, odds ratio; TV, Trichomonas vaginalis. 
aAdjusted for sexually transmitted and reproductive tract coinfection, gravidae, and human immunodeficiency virus coinfection.
bSyphilis and any other infection(s) refers to any other curable sexually transmitted or reproductive tract infection and/or malaria.
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produce some notable imbalances in subgroups as reflected by 
some P values. However, confounding is not inherently pro-
duced by imbalances in group sizes. Rather, confounding is 
determined by observing the difference between crude ORs and 
adjusted ORs specific to a variable of interest [19]. We identi-
fied the following 3 confounders in this process: hypertension 
at enrollment or delivery (change in crude OR = 13.39%) in the 
stillbirth analysis (Supplementary Table 3); prior preterm birth 
(change in crude OR = 14.04%) in the preterm delivery analysis 
(Supplementary Table 5), and prior miscarriage (change in crude 
OR = 25.73%) in the IUGR analysis (Supplementary Table 6).
There were 3 statistically significant differences between 
women who were given 0–1 dose vs ≥2 doses, as follows: the 
wealth quintiles (P = .048), sex of the baby (P = .008), and 
malaria infection (P = .047; Table 1). Differences in wealth may 
not have had a consequential effect on outcomes because the 
imbalance straddles the 2 exposure groups; the lowest (poor-
est) quintile has proportionately more women from the ≥2 dose 
group; the second and third quintiles have more women from 
the 0–1 dose group; the fourth quintile has more women from 
the ≥ 2 dose group; and the highest (wealthiest) quintile has near 
equivalent representation from the 2 dose group. Regarding sex 
of the baby, there were fewer males born than females in the 0–1 
dose group, 38.1% males (n = 48) and 61.9% females (n = 78) 
relative to 51.4% (n = 303) males and 48.6% (n = 287) females 
born to mothers who received ≥2 doses. However, this difference 
is unlikely to have influenced the protective effect of IPTp-SP. As 
for malaria infection at enrollment, 10% more women were par-
asitemic and went on to receive ≥2 doses of IPTp-SP compared 
to recipients of 0–1 dose (59.3% [n = 346] vs 49.2% [n = 62]; P = 
.047). This finding is consistent with the epidemiology of malaria 
in pregnancy and can be expected from the standpoint of health 
service delivery. Among women enrolled between 8 and 13 ges-
tational weeks, 36.1% (95% CI, 22.5, 52.5) had peripheral par-
asitemia; these same women went onto receive a mean of 2.6 
doses of IPTp-SP over the course of their pregnancies. However, 
peripheral malaria was lower (33.5%; 95% CI, 29.1, 38.3) among 
participants who were between 14 and 20 gestational weeks at 
the time of their enrollment and subsequently received a mean 
of 2.4 doses of IPTp-SP during their pregnancies. These 2 trends 
of parasitemia and the number of IPTp-SP doses continued 
downward when women who were between 21 and 26 gesta-
tional weeks were considered and 27 to 31 gestational weeks 
at their time of enrollment. These two trends of parasitemia 
and the number of IPTp-SP doses continued downward when 
comparing women at enrollment who were between 21 and 26 
gestational weeks versus 27 to 31 gestational weeks; peripheral 
parasitemia was 31.7% (95% CI, 27.5, 36.2) and 27.6% (95% CI, 
21.9, 34.2), and the mean number of IPTp-SP doses adminis-
tered until delivery was 2.2 and 1.8, respectively. In our study, 
parasite load was highest among women enrolled at gestational 
week 15, with a mean density of 4752 parasites per microliter 
of blood. This peak of parasite density is also consistent with 
the epidemiology of malaria infection during pregnancy; prior 
reports suggest that peripheral parasitemia peaks between weeks 
9 and 16 and tapers to term [32, 33]. Thus, our results confirm 
that pregnant women who seek ANC services earlier in their 
pregnancies are more likely to have a malaria infection; they are 
also more likely to receive more doses of IPTp-SP during preg-
nancy for having engaged the health system earlier in pregnancy.
Our last notable imbalance was in the proportion of pregnant 
women from households where indoor residual spraying had 
been applied in the previous 12 months (P = .002). This was appli-
cable to 17.1% (n = 51) of women in the 2 dose group compared 
to 28.4% (n = 76) in the ≥3 dose group (Supplementary Table 1). 
Although indoor residual spraying is known to protect against 
malaria infection, this did not translate into reduced parasitemia 
at enrollment, as measured by polymerase chain reaction; 56.1% 
(n = 171) of women in the 2 dose group had malaria infections, 
whereas 62.9% (n = 175) in the ≥3 doses group were parasitemic.
As a nonrandomized observational study, we can only con-
clude that our results reflect associations between the exposure 
to IPTp-SP doses during ANC visits and birth outcomes and 
the actual mechanisms of action are unknown. Nevertheless, 
these observations are biologically plausible and compelling. In 
fact, because only 6 of the 126 women in the 0–1 dose group 
received 0 doses in our study, the protective effect of IPTp-SP 
against adverse birth outcomes related to malaria and curable 
STIs/RTIs is likely higher than we observed.
Our study also illustrates the importance of improving syph-
ilis screening and treatment. Results from RPR assays were not 
available on the same day as sample collection. Thus, Ministry 
staff hand-deliver test results to RPR-positive pregnant women 
at their homes 3 days later and encourage patients to return 
to the health center with their partners for treatment.  Facility 
staff make another home visit if RPR-positive women have not 
sought treatment within 4 weeks. Despite these efforts, only 
64.1% (n = 52) of women received appropriate treatment. Use 
of rapid point-of-care tests for syphilis would allow for same-
day screening and treatment [34].
It is important to consider our results in the context of the 
current research agenda. We know that dihydroartemisinin–
piperaquine, when administered as IPTp, is superior to SP 
against the incidence of clinical malaria during pregnancy and 
the risk of maternal anemia at delivery [24]. Consequently, SP 
is suboptimal for preventing and clearing malaria infection 
in pregnant women. However, our results suggest that candi-
date replacements for SP should offer protection that extends 
beyond malaria infection to include curable STIs/RTIs. A sys-
tematic review and metaanalysis found that the prevalence of 
curable STIs/RTIs was similar, if not higher, when considered 
collectively than malaria infection among pregnant women 
attending ANC facilities in sub-Saharan Africa [35]. Pooled 
estimates for eastern and southern Africa were as follows: 
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syphilis, 4.5% (3.9%–5.1%); N. gonorrhoeae, 3.7% (2.8%–4.6%); 
C. trachomatis, 6.9% (5.1%–8.6%); T. vaginalis, 29.1% (20.9%–
37.2%); bacterial vaginosis, 50.8% (43.3%–58.4%); peripheral 
malaria, 32.0% (25.9%–38.0%); and placental malaria, 25.8% 
(19.7%–31.9%). Depending on the specific STI/RTI, the associ-
ation with poor birth outcomes may not be as great as malaria 
infection.
Alternative therapies for use in IPTp must offer broad-spec-
trum protection against malaria and curable STIs/RTIs. A 
combination such as dihydroartemisinin–piperaquine plus 
azithromycin may address this public health need and war-
rants investigation. Azithromycin has preventive and curative 
effects against syphilis, N. gonorrhoeae, C. trachomatis, and 
potentially T. vaginalis [36]. Management of bacterial vaginosis 
in pregnancy may be more difficult. Authors of a recent sys-
tematic review found strong evidence against the use of met-
ronidazole to reduce the risk of preterm birth. Metronidazole 
treatment among women in low-risk pregnancies appeared to 
increase preterm births (risk ratio, 1.11; 95% CI, 0.93, 1.34) 
and offered no effect in high-risk pregnancies (risk ratio, 0.96; 
95% CI, 0.78, 1.18). In contrast, clindamycin reduced the risk 
of preterm birth by 13% (risk ratio, 0.87; 95% CI, 0.73–1.05) 
[37], is safe in pregnancy, is well tolerated, and has been used as 
monotherapy for the treatment of uncomplicated Plasmodium 
falciparum infection [38]. There is a need to conduct longitu-
dinal studies to investigate the potential protective effect of 
treatments that involve dihydroartemisinin–piperaquine plus 
azithromycin and/or clindamycin that also involve the use of 
postpartum anthropometry to measure reductions in infant 
stunting [39].
CONCLUSIONS
In this prospective cohort study of pregnant women in Zambia, 
the administration of ≥2 doses of IPTp-SP compared to 0–1 dose 
appeared to protect against adverse birth outcomes; ≥3 doses was 
associated with still greater protection. This dose-response rela-
tionship was significant in reducing the odds of preterm delivery. 
Additional research, including longitudinal studies, are needed to 
improve our understanding of the potential for IPTp-SP to protect 
against STIs/RTIs and other nonmalarial causes of adverse birth 
outcomes.
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